entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 16:36:19 - browse：277

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Paying for Covid pills will soon shift to insurers

WSS

Leading voice in opioid treatment defends methadone clinic system

U.K. researchers warn about biases in medical devices, algorithms

Medtronic CEO on promising devices for diabetes, hypertension

Colonoscopy prep: Liquid

Biden's order seeks to regulate AI risk without stifling innovation

Methadone treatment changes are coming. Do they go far enough?

hotspot

entertainment

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Leading voice in opioid treatment defends methadone clinic system

Medicare proposal to cover medical devices draws a mixed reaction

Creating egg and sperm cells from stem cells raises ethical issues

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth increases loan offers after Change Healthcare outage

DIEP, the 'gold standard' of breast reconstruction, is under threat

Telehealth options flood the market as retailers push virtual care

23andMe had bad news about my health. I wish a person had delivered it

Emergency medicine has repudiated 'excited delirium.' Now what?

hotspot

5 to watch: Tech startups trying to solve health care's staffing crisis

Testing for cancer recurrence creates a new limbo for patients

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Intermittent fasting comes with a heart risk? Not so fast

Orchard's therapy for neuron disease in children wins FDA approval

Emergency medicine has repudiated 'excited delirium.' Now what?

Wikipedia

knowledge

hotspot

explore